Responses

Download PDFPDF
Letter
Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses [https://authors.bmj.com/after-submitting/rapid-responses/].
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses [https://www.bmj.com/company/journals-terms-and-conditions-for-rapid-responses/] and understand that your personal data will be processed in accordance with those terms and our privacy notice [https://www.bmj.com/company/your-privacy/].
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Area postrema syndrome: another feature of anti-GFAP encephalomyelitis
    • Jonathan Ciron, Neurologist University Hospital of Toulouse, France
    • Other Contributors:
      • Damien Biotti, Neurologist
      • Thierry Tchoumi, Neurologist
      • Marie Benaiteau, Neurologist
      • Nicolas Maubeuge, Neurologist
      • Romain Marignier, Neurologist

    Dear Editor,

    We read with great interest the recent paper of Sechi et al. that describes 13 patients with anti-GFAP related myelitis and compares them with 41 patients with anti-AQP4 related myelitis.1 To date, very little data is available about anti-GFAP related disorders.2-3 Sechi et al. highlight some differences between the two entities to help clinicians differentiate them.1 One of these clinical differences relates to area postrema syndrome (APS). Indeed, it is well known that APS is a classical feature of neuromyelitis optica spectrum disorders, particularly among anti-AQP4 positive patients.4 Sechi et al. report this syndrome as a prodromal event in 20% of anti-AQP4 related myelitis. Conversely, the authors do not report any case of APS preceding or accompanying myelitis related to anti-GFAP.1 Given these data, APS could be an indicator for ruling out anti-GFAP encephalomyelitis, particularly useful for centers that do not yet have access to biological testing for anti-GFAP Abs.
    However, we report the case of a 41-year-old woman who in April 2016 developed intractable nausea and vomiting lasting for five weeks and leading to 35 kilograms in weight loss. An extensive search for a digestive disease was negative, and no neurological explorations were performed. One month following the resolution of digestive symptoms, she developed mental confusion, diplopia, dysarthria, dizziness, bilateral blurred vision (with optic disc edema) and paraparesis. Brain...

    Show More
    Conflict of Interest:
    None declared.